Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Allogeneic Hematopoietic Cell Transplantation Using Post-transplantation Cyclophosphamide for Graft-versus-host Disease Prophylaxis in Higher-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, and Secondary AML Patients

NCT06098313 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT06098313
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06098313 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Allogeneic Hematopoietic Cell Transplantation Using Post-transplantation Cyclophosphamide for Graft-versus-host Disease Prophylaxis in Higher-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, and Secondary AML Patients
Lead sponsor
Asan Medical Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
July 1, 2020
Completion date
May 31, 2027
Enrollment
113 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

patients with mds, acute myeloid leukemia (aml) evolving from mds, and chronic myelomonocytic leukemia (cmml)